TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04585815
Drug: Sasanlimab
Normalized name: Sasanlimab
DrugBank: Sasanlimab (DB18849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: solution supplied in vials
Study: NCT04585815
Drug: Axitinib
Normalized name: Axitinib
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tablets
Study: NCT02324387
Drug: Tc99m sestamibi
Normalized name: TECHNETIUM TC-99M SESTAMIBI 1 mg in 10 mL INTRAVENOUS INJECTION [Kit for the Preparation of Technetium Tc99m Sestamibi]
DrugBank: Technetium Tc-99m sestamibi (DB09161)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mCi of 99mTc sestamibi by vein before each molecular breast imaging (MBI).
Study: NCT01228045
Drug: Trastuzumab in Combination with TS-ONE and cisplatin
Normalized name: Cisplatin
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects will receive treatment that combined TS-ONE, cisplatin and trastuzumab every 3 weeks in this study. This 3 weeks period of time is called a cycle. The cycle will be repeated until subject experience disease progression or unbearable toxicities or they choose to withdraw from the study. Each cycle is numbered in order.
Study: NCT00804271
Drug: memantine
Normalized name: Memantine
DrugBank: Memantine (DB01043)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: memantine tablets, OD, 12 weeks
Study: NCT00077194
Drug: romidepsin
Normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01526980
Drug: biphasic insulin aspart 30
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administrated subcutaneously (s.c., under the skin) once daily before dinner for 30 days in each treatment period
Study: NCT01526980
Drug: biphasic insulin aspart 70
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administrated subcutaneously (s.c., under the skin) twice daily before breakfast and lunch for 30 days in each treatment period
Study: NCT01526980
Drug: biphasic human insulin 30
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administrated subcutaneously (s.c., under the skin) twice daily before breakfast and dinner for 30 days in each treatment period
Study: NCT03574649
Drug: Nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
Study: NCT03574649
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: (SP-4-2)-diamminedichloroplatinum(II)
Study: NCT02932943
Drug: Rapastinel
Normalized name: Rapastinel
DrugBank: Rapastinel (DB11801)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapastinel pre-filled syringes for weekly IV injections.
Study: NCT01506076
Drug: Levocetirizine DiHCl
DrugBank: Cetirizine (DB00341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levocetirizine DiHCl Tablets 5 mg
Study: NCT00165074
Drug: Infasurf (drug)
DrugBank: Calfactant (DB06415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infasurf 3 cc/kg instilled via endotracheal tube q 12-24 hours x 2 doses
Study: NCT00058292
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Part of high dose BEAM chemotherapy given on study (a combination of carmustine, etoposide, cytarabine, and melphalan). Cytarabine is given at a dose of 100 mg/m2 intravenous infusion over a 1 hour period, every 12 hours on treatment days -5, -4, -3, and -2, for a total of 8 doses (Day 0 = stem cell transplant).
Study: NCT00058292
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Part of high dose BEAM chemotherapy given on study (a combination of carmustine, etoposide, cytarabine, and melphalan). Etoposide is given at a dose of 100 mg/m2 intravenous infusion over a 2 hour period every 12 hours on treatment days -5, -4, -3, and -2, for a total of 8 doses (Day 0 = stem cell transplant).
Study: NCT00058292
Drug: melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Part of high dose BEAM chemotherapy given on study (a combination of carmustine, etoposide, cytarabine, and melphalan). Melphalan is given at a dose of 140 mg/m2 as an intravenous infusion over a 1 hour period on treatment day -1 (Day 0 = stem cell transplant).
Study: NCT00577460
Drug: Pramipexole
Normalized name: Pramipexole
DrugBank: Pramipexole (DB00413)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pramipexole ER 0.375 -4.5 mg
Study: NCT00914667
Drug: warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single Dose Warfarin 25 mg on Day 1
Study: NCT00914667
Drug: Warfarin plus Fesoterodine
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fesoterodine 8 mg ER tablets QD for 9 Days and Single Dose Warfarin 25 mg on Day 3
Study: NCT00352261
Drug: Esomeprazole
Normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00352261
Drug: Lansoprazole
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01001208
Drug: Etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1 mL for subcutaneous injection
Study: NCT01641445
Drug: Topiramate
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate (200 mg daily)
Study: NCT00551005
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00495326
Drug: Nevirapine based therapy
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * Patients below 60 kg: 1 tablet twice a day of Triomune30®, including NVP 200 mg, 3TC 150 mg and D4T 30mg~* Patients above 60kg: 1 tablet twice a day of Triomune40®, including NVP 200 mg, 3TC 150 mg and D4T 40 mg)
Study: NCT00495326
Drug: Efavirenz based therapy
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Efavirenz EFV 200 mg (3 tablets/d) Lamivudine 3TC 300mg (2 tablets of 150mg/d) D4T generic 30mg or 40mg (2 tablets/d)
Study: NCT00495326
Drug: Rifampicin (RMP) Ethambutol (E) Isoniazid (H) Pyrazinamid (Z)
Normalized name: rifampicin, pyrazinamide and isoniazid
DrugBank: Ethambutol (DB00330)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * Intensive phase: 2 months daily E(RMP)HZ. PTB smear positive patients at month 2 will receive 1 more month intensive phase.~* Continuation phase: 4 months daily H(RMP).~* Patients with meningitis will receive Streptomycin instead of E during intensive phase.
Study: NCT04193566
Drug: Forxiga
Normalized name: Farxiga
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Forxiga®, dapagliflozin 10 mg film-coated tablet.~For further information please refer to:~https://www.ema.europa.eu/en/documents/product-information/forxiga-epar-product-information_en.pdf.~Common side effects include hypoglycemia, hypotension, elevated hematocrite, dyslipidemia, back pain, dizziness, skin rash, urinary tract infection, vulvovaginitis and dehydration. Very rare incidents of ketoacidosis have been observed. Side effects have only been observed after use in longer periods and not in single-dose usage, as planned in the present study. A dose of 50 mg has been chosen to achieve optimal efficacy. Once-per-day doses of dapagliflozin for 12 weeks of 2.5 mg, 5 mg, 10 mg, 20 mg and 50 mg have been demonstrated to be relatively safe across the mentioned doses (20) and no apparent risk is expected from instituting two single-doses of 50 mg dapagliflozin.
Study: NCT01814085
Drug: Escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Escitalopram tablets will be administered orally in the dose range of 10 to 20 milligram per day (mg/day) for 8 weeks. Dose can be adjusted as per Investigator's discretion depending on participant's response.
Study: NCT00970281
Drug: Rapid-Acting Intramuscular Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered by means of intramuscular injection (IM) with the possibility of second 10 milligram (mg) injection 2 to 4 hours after first injection, for a maximum of 2 injections
Study: NCT00408902
Drug: tandutinib
Normalized name: Tandutinib
DrugBank: Tandutinib (DB05465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally, 500 mg bid daily
Study: NCT03874130
Drug: Scopolamine
Normalized name: Scopolamine
DrugBank: Scopolamine (DB00747)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV Scopolamine
Study: NCT03574649
Drug: Aldoxorubicin
Normalized name: Aldoxorubicin
DrugBank: Aldoxorubicin (DB06013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: INNO-206
Study: NCT03574649
Drug: Avelumab
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
Study: NCT03574649
Drug: ALT-803
Normalized name: ALT-803 COMPONENT IL-15R.ALPHA.SU/FC FUSION PROTEIN
DrugBank: Inbakicept (DB16479)
Approvals — FDA: no, EMA: no, PMDA: no
Description: recombinant human super agonist interleukin-15 (IL-15) complex \[also known as IL-15N72D:IL-15RαSu/IgG1 Fc complex\]
Study: NCT03574649
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel
Study: NCT03574649
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: carboplatin
Study: NCT03054103
Drug: Midazolam + Ketamine 10 MG/ML: 0.5 ML
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5 mg ketamine IV given just prior to onset of case. Then titrated midazolam up to 2 mg IV at beginning and during case.
Study: NCT03054103
Drug: Midazolam + Ketamine 10 MG/ML: 1 ML
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10 mg ketamine IV given just prior to onset of case. Then titrated midazolam up to 2 mg IV at beginning and during case.
Study: NCT03054103
Drug: Midazolam + Normal saline
Normalized name: NS-2359
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Preoperative control: Normal saline placebo given preoperatively. Then protocol followed for titration of midazolam up to 2 mg IV at beginning and during case.
Study: NCT01454284
Drug: Glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01454284
Drug: Insulin Lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02665117
Drug: Potassium Magnesium Citrate (KMgCit)
Normalized name: Potassium
DrugBank: Potassium citrate (DB09125)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: KMgCit will be administer for 4 months with chlorthalidone.
Study: NCT02665117
Drug: Potassium Chloride (KCl)
Normalized name: Potassium Chloride
DrugBank: Potassium chloride (DB00761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: KCl will be administer for 4 months with chlorthalidone.
Study: NCT02320409
Drug: Sulfatinib
Normalized name: SULFATINIB
DrugBank: Surufatinib (DB15106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250mg Sulfatinib ,single dose,oral
Study: NCT01345799
Drug: TRK-170
Normalized name: TRK-250
DrugBank: TRK-250 (DB18500)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04464460
Drug: TAK-671
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-671 intravenous infusion.
Study: NCT00001805
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00195325
Drug: TTI-237
Normalized name: TTI-101
DrugBank: TTI-101 (DB17578)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01091259
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01091259
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01750437
Drug: YH1885L(Revaprazan)
Normalized name: Revaprazan
DrugBank: Revaprazan (DB16308)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01750437
Drug: Esomeprazole 20mg
Normalized name: ESOMEPRAZOLE 20MG (BASE) CAP,EC
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02254824
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin
Study: NCT00022477
Drug: BMS-247550
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01732692
Drug: MOVIPREP
Normalized name: MoviPrep
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MOVIPREP solution
Study: NCT02052635
Drug: ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single loading dose of 180mg of ticagrelor at time of bivalirudin administration. Beginning 12 hrs following study drug administration, all pts in the ticagrelor arm will receive ticagrelor 90 mg (maintenance dose) approximately every 12 hrs until Follow-up telephone contact.
Study: NCT02052635
Drug: clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Single loading oral dose of 600 mg of clopidogrel will be given at time of bivalirudin administration. Beginning 4 hrs following study drug administration, all pts in the clopidorgrel arm will receive ticagrelor 180 mg for the loading dose, followed by 90 mg maintenance dose approximately every 12 hours until the Follow-up telephone contact.
Study: NCT03703063
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered by intravenous infusion over 30 minutes.
Study: NCT03703063
Drug: nab paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered by intravenous infusion over 30-40 minutes.
Study: NCT03703063
Drug: Onivyde
Normalized name: Onivyde
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered by intravenous infusion over 90 minutes.
Study: NCT03703063
Drug: 5-fu
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered by intravenous infusion over 46 hours.
Study: NCT03079830
Drug: Piritramid
Normalized name: Piritramida
DrugBank: Piritramide (DB12492)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piritramid will be administered i.v., if the patients feel pain after receiving a bolus of Ropivacaine or saline through the catheter.
Study: NCT03079830
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Piritramid will be administered i.v., if the patients feel pain after receiving a bolus of Ropivacaine or saline through the catheter.
Study: NCT00028691
Drug: chlorambucil
Normalized name: Chlorambucil
DrugBank: Chlorambucil (DB00291)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03394209
Drug: Favipiravir
Normalized name: favipiravir
DrugBank: Favipiravir (DB12466)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: In first step: favipiravir tablet is orally administered. This drug will be given twice daily for a 10-day period. For the First day, the dosage is 1600 mg twice daily. Starting from the second day, the dosage is 600 mg twice daily.~In second step: favipiravir tablet is orally administered. This drug will be given twice daily for a 10-day period. For the First day, the dosage is 1800 mg twice daily. Starting from the second day, the dosage is 800 mg twice daily.
Study: NCT03394209
Drug: Oseltamivir 75Mg Capsule
Normalized name: oseltamivir
DrugBank: Oseltamivir (DB00198)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oseltamivir will be administered at 75mg twice daily orally for 10 days
Study: NCT01150747
Drug: ceftriaxone
Normalized name: Ceftriaxone
DrugBank: Ceftriaxone (DB01212)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 250mg IM once
Study: NCT00636896
Drug: Olanzapine plus modafinil
Normalized name: Modafinil
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Olanzapine 10 mg/d plus modafinil 200 mg/d
Study: NCT00636896
Drug: Olanzapine plus placebo
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine 10 mg/d plus placebo
Study: NCT02744352
Drug: 0.2% of ropivacaine at 8 milliliter/hour
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local anesthetic
Study: NCT01937390
Drug: Tiotropium 2x2.5µg tiotropium (equivalent to 2x3.154µg tiotropium bromide monohydrate) Respimat® inhaler and cartridge Solution for inhalation
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Respimat® inhaler and cartridge Solution for inhalation
Study: NCT01937390
Drug: Tiotropium 18µg (equivalent to 22.5µg tiotropium bromide monohydrate) HandiHaler® device Inhalation powder, hard capsule
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HandiHaler® device Inhalation powder, hard capsule
Study: NCT00060905
Drug: Divalproex Sodium (Depakote ER)
Normalized name: DIVALPROEX
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01874951
Drug: Naltrexone
Normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 mg of naltrexone will be given twice daily to all patients assigned to active drug.
Study: NCT00483496
Drug: bisoctrizole 10% alone (formula RV3131A-MV1237)
DrugBank: Bisoctrizole (DB11262)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00483496
Drug: Ti02 microfine 12.15% + bisoctrizole 10% (formula RV3131A-MV1329)
DrugBank: Bisoctrizole (DB11262)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00483496
Drug: Ti02 pigmentary 3% + bisoctrizole 10% (formula RV3131A-MV1212)
DrugBank: Bisoctrizole (DB11262)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00483496
Drug: Ti02 microfine 12.15% + Ti02 pigmentary 3% + bisoctrizole 10% [V0096 CR (formula RV3131A-MV1166)]
DrugBank: Bisoctrizole (DB11262)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00671060
Drug: Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mcg buccal misoprostol administered every 6 hours for up to 48 hours until fetus is delivered.
Study: NCT00671060
Drug: Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mcg buccal misoprostol administered every 6 hours for upto 48 hours
Study: NCT01548235
Drug: biphasic insulin aspart 30
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Prescribed biphasic insulin aspart 30 as part of routine care. Starting dose, dose titration and injection frequency determined individually by each physician.
Study: NCT01214122
Drug: Warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 x 2.5 (25) mg orally once daily on day 1 and on day 14
Study: NCT00025337
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00407511
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin will be administered orally, twice a day for 12 weeks, including 4-week dose adjustment phase followed by 8-week maintenance phase. The minimum allowable pregabalin dose during the trial will be 75 mg BID (150 mg/day) and the maximum allowable dose will be 300 mg BID (600 mg/day).
Study: NCT01374737
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: dexmedetomidine, 0.1ug/kg up or down
Study: NCT00671749
Drug: adapalene gel, 0.3%
DrugBank: Adapalene (DB00210)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Applied once daily at bedtime
Study: NCT00529035
Drug: Interleukin-2
Normalized name: INTERLEUKIN-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose will vary depending upon when participant enters the trial: Given as a daily injection under the skin for 8 weeks.
Study: NCT02515227
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Humanized monoclonal antibody (mAb) specific for PD-1.
Study: NCT02130440
Drug: Resveratrol nasal spray
DrugBank: Resveratrol (DB02709)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01622322
Drug: Nitrous Oxide
Normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitrous Oxide, 70%, O2 30%) 1-5 L, Sevoflurane 1-2%, ETCO2: 32-35 mmHg.
Study: NCT04067999
Drug: Semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.The decision to initiate treatment with semaglutide is at the treating physician's discretion, and clearly separated from the decision to include the patient in the study.
Study: NCT00275613
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The Rituximab dose is 1000 mg (1 gm) given as an IV infusion every two weeks for 2 doses (days 1 and 15)
Study: NCT03822182
Drug: liposomal bupivicaine
Normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The medication administered in the interscalene block is the intervention in this study. There are three different types of interscalene blocks that will be administered in order to compare the independent effectiveness of LB with the effectiveness of LB plus dexamethasone. Study participants will be randomized into one of three groups. The treatment groups are listed below:~Group 1 (Control): 30 ml of 0.5% bupivacaine and 0.4ml (4 mg) of dexamethasone Group 2: 15ml 0.5% bupivacaine and 10ml (133mg) of LB (Exparel) and 5.4ml normal saline Group 3: 5ml 0.5% bupivacaine and 10ml LB (Exparel) and 0.4ml (4 mg) dexamethasone and 5ml normal saline
Study: NCT03822182
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: steroid that will be used in control as well as in group 3 to see if effect with liposomal bupivicaine is prolonged as has been shown with standard bupivicaine.
Study: NCT00524381
Drug: Etanercept (Enbrel)
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: TNF-alpha antagonist, subcutaneous injection, 25 mg twice/week, 14 days.